|
Price : 5 slide for 600 $
CSA2 Human, liver cancer | |||||||
Age | Sex | Organ | Diagnosis | TNM | Stage | Months* | |
1 | 41 | M | liver | HCC | T3N0M0 | ⅢA | . |
2 | 52 | M | liver | HCC | T3N0M0 | ⅢA | . |
3 | 56 | M | liver | HCC | T3N0M0 | ⅢA | . |
4 | 37 | M | liver | HCC | T4NxM1 | Ⅳ | . |
5 | 32 | M | liver | HCC | T3N0M0 | ⅢA | . |
6 | 57 | M | liver | HCC | T3N0M0 | ⅢA | . |
7 | 65 | M | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
8 | 72 | M | liver | well & poorly differentiated HCC | T2N0M0 | Ⅱ | . |
9 | 58 | F | liver | well differentiated HCC | T2N0M0 | Ⅱ | . |
10 | 52 | M | liver | well differentiated HCC | T2N0M0 | Ⅱ | . |
11 | 40 | M | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
12 | 67 | M | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
13 | 20 | M | liver | well differentiated HCC | T4N0M0 | ⅢB | . |
14 | 48 | M | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
15 | 47 | M | liver | HCC | T1N0M0 | Ⅰ | . |
16 | 69 | F | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
17 | 63 | F | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
18 | 60 | F | liver | poorly differentiated HCC | T2N0M0 | Ⅱ | . |
19 | 66 | F | liver | well differentiated HCC | T2N0M0 | Ⅱ | . |
20 | 64 | M | liver | poorly differentiated HCC | T3N0M0 | ⅢA | . |
21 | 64 | M | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
22 | 51 | M | liver | moderately differentiated HCC | T4N0M0 | ⅢB | . |
23 | 65 | F | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
24 | 41 | M | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
25 | 57 | F | liver | well differentiated HCC | T2N0M0 | Ⅱ | . |
26 | 57 | M | liver | moderately differentiated HCC | T3N0M0 | ⅢA | . |
27 | 50 | M | liver | poorly differentiated HCC | T2N0M0 | Ⅱ | . |
28 | 43 | M | liver | moderately differentiated HCC | T2N0M0 | Ⅱ | . |
29 | 60 | F | liver | poorly differentiated HCC | T4N0M0 | ⅢB | . |
30 | 64 | M | liver | moderately differentiated HCC | T3N1M0 | ⅢC | . |
31 | 52 | M | liver | moderately differentiated HCC | T3N1M0 | ⅢC | . |
32 | 54 | M | liver | moderately differentiated HCC | T4NxM1 | Ⅳ | . |
33 | 56 | M | liver | well differentiated HCC | T3N0M0 | ⅢA | . |
34 | 77 | M | liver | moderately differentiated HCC | T3N0M0 | ⅢA | . |
35 | 38 | M | liver | HCC | T1NxM0 | Ⅰ | . |
36 | 75 | M | liver | moderately differentiated HCC | T2N0M1 | Ⅳ | . |
37 | 43 | M | liver | moderately differentiated HCC | T3N0M0 | ⅢA | . |
38 | 72 | M | liver | moderately differentiated HCC | T4N1M0 | ⅢC | . |
39 | 60 | F | liver | cholangiocarcinoma | T2N0M0 | Ⅱ | . |
40 | 58 | M | liver | cholangiocarcinoma | T3N1M1 | Ⅳ | . |
41 | 51 | M | colon | metastatic HCC | M1 | Ⅳ | . |
42 | 62 | M | lung | metastatic HCC | M1 | Ⅳ | . |
43 | 61 | M | lung | metastatic HCC | M1 | Ⅳ | . |
44 | 60 | M | adrenal gland | metastatic HCC | M1 | Ⅳ | . |
45 | 47 | M | lumbar vertebra | metastatic HCC from #35 | . | . | 22 |
46 | 75 | M | colon | metastatic HCC from #36 | . | . | 0 |
47 | 43 | M | soft tissue | metastatic HCC from #37 | . | . | 5 |
48 | 72 | M | lymph node | metastatic HCC from #38 | . | . | 0 |
49 | 60 | F | soft tissue | metastatic cholangiocarcinoma from #39 | . | . | 16 |
50 | 58 | M | lymph node | metastatic cholangiocarcinoma from #40 | . | . | 0 |
51 | 57 | M | liver | normal liver (adjacent to cancer, match of #6) | . | . | . |
52 | 72 | M | liver | normal liver (adjacent to cancer, match of #8) | . | . | . |
53 | 58 | F | liver | normal liver (adjacent to cancer, match of #9) | . | . | . |
54 | 52 | M | liver | normal liver (adjacent to cancer, match of #10) | . | . | . |
55 | 67 | M | liver | normal liver (adjacent to cancer, match of #12) | . | . | . |
56 | 32 | M | liver | normal liver (apart from cancer, match of #5) | . | . | . |
57 | 63 | F | liver | normal liver (apart from cancer, match of #17) | . | . | . |
58 | 65 | F | liver | normal liver (apart from cancer, match of #23) | . | . | . |
59 | 57 | F | liver | normal liver (apart from cancer, match of #25) | . | . | . |
60 | carbon | ||||||
HCC: hepatocellular carcinoma | |||||||
*: interval between primary and metastatic cancer | |||||||
TNM Classification : Liver carcinoma (AJCC 6th Edition) |
General Information of the Tissue Array Slide :
Applications
- Immunohistochemistry
- In situ hybridization, RNA or DNA
- Fluorescent in situ hybridization (FISH)
- In situ PCR, RNA or DNA
- TUNEL for apoptosis (Recommended procedures in www.tissue-array.com -> protocol)
Storage and stability
- Individual slide is paraffin-coated and put in an air-tight pack with inert gas.
- Tissue array slides are shipped in room temperature.
- If the slides are stored in 4 degree, they are good up to one year.
How processed
- Tissues were initially fixed with formalin except for some of the animal tissues.
- Then, dehydrated with gradient ethanol; typically 1 hour each progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Microtoming in 4 µm thickness and put on silane coating slide from Muto Pure Chemicals (Japan)
Before use
- Dry slides for 1 hour in a oven at 60 degree.
- Dewax slides in xylene for 4 minutes x 5 times
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times each.
- Immerse slides in tap water for 5 minutes
Slide orientation
- In most of the slides with 59 or 60 cores, the orientation is as below unless indicated otherwise. #60 location is usually filled with carbon for orientation.
Shaded area |
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 |
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 |
31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 |
41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 |